Why the study?
Does low-molecular-weight heparin (LMWH) reduce cancer mortality compared to oral anticoagulants in patients treated for venous thromboembolism?
Population
1,726 patients from 8 randomized studies treated for the prevention of recurrent venous thromboembolism.
Comparison
Low-molecular-weight heparin for at least 3… vs Oral anticoagulants (OA).
Design
Meta-analysis, randomized
Follow-up
mean 8.6 months
Authors
Loading...
LMWH confers no cancer mortality advantage over oral anticoagulants in VTE; confirms equivalent survival and supports therapy selection by other clinical factors.
Does low-molecular-weight heparin (LMWH) reduce cancer mortality compared to oral anticoagulants in patients treated for venous thromboembolism?
Long-term treatment (≥3 months) with low-molecular-weight heparin does not improve cancer survival compared to oral anticoagulants in patients with venous thromboembolism.
Conti et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: